1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street

Prosper Junior Bakiny, The Motley Fool

Sat, Mar 22, 2025, 10:56 AM 4 min read

Iovance Biotherapeutics (NASDAQ: IOVA) is simply a biotech institution with an innovative attack to processing crab medicines. Though the institution reached a important milestone past twelvemonth -- with regulatory support of a cardinal therapy -- its shares person importantly lagged the market.

The banal is down by 74% implicit the trailing-12-month play and, astatine nether $4 per share, is hardly supra its 52-week low. Still, Wall Street analysts are bullish connected Iovance. Their lowest terms people is $6, the highest is $32, and the mean is $19.54, according to Yahoo! Finance.

Do Iovance's prospects warrant these projections? Here's what investors request to cognize astir this small-cap biotech company.

Iovance Biotherapeutics develops therapies that harness the powerfulness of tumor-infiltrating lymphocytes (TILs), immune cells that tin people and destruct crab cells. Iovance's TIL-based treatments are made from the patient's cells done a proprietary procedure. The company's Amtagvi, a medicine for melanoma that earned support from the U.S. Food and Drug Administration (FDA) past year, takes 34 days to manufacture.

Amtagvi became the archetypal therapy of its benignant to notch an denotation to dainty a coagulated tumor, demonstrating Iovance's innovative capabilities. The patient-specific attraction does look immoderate issues, though, including the 34 days it takes to make. Complicating matters adjacent more, Amtagvi is administered successful specialized attraction centers. This costly and lengthy process makes it challenging to rotation retired the merchandise to capable patients to make important income portion keeping costs down.

Still, Iovance is making progress. Last year, it reported $164.1 cardinal successful gross (the magnitude it had successful 2023 was not meaningful). It's lone begun to scratch the aboveground of the 20,000 patients with melanoma eligible for Amtagvi successful the U.S. And the institution is seeking to gain support for the medicine successful much countries: It could get the motion successful the U.K., the European Union, and Canada successful 2025, and inactive get regulators connected committee successful different countries adjacent year.

There is simply a monolithic marketplace here: Iovance estimates 325,000 yearly cases of melanoma worldwide. If the institution makes important headway successful its addressable market, Iovance's income volition proceed moving successful the close direction.

Many investors interest that Iovance Biotherapeutics volition person occupation becoming profitable, owed to the costly and lengthy TIL manufacturing process. That's 1 of the reasons the banal continues to lag the market, and it is a morganatic concern. It's besides indispensable to origin successful imaginable regulatory setbacks for Amtagvi.